Provided by Tiger Trade Technology Pte. Ltd.

AngioDynamics

15.11
-0.0100-0.07%
Post-market: 15.150.0400+0.26%19:42 EDT
Volume:1.13M
Turnover:17.07M
Market Cap:635.44M
PE:-17.08
High:15.36
Open:15.36
Low:15.00
Close:15.12
52wk High:16.29
52wk Low:9.39
Shares:42.05M
Float Shares:32.51M
Volume Ratio:1.68
T/O Rate:3.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8848
EPS(LYR):-0.8848
ROE:-20.77%
ROA:-5.13%
PB:3.72
PE(LYR):-17.08

Loading ...

Angiodynamics Q4 Sales Beat Estimates on Med Tech Strength

Reuters
·
Jul 14

AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate

Benzinga Earnings
·
Jul 14

Angiodynamics Q4 FY26 Adjusted Loss Per Share Widens to $0.07; Net Sales Rise 8% to $86.6 Million

Reuters
·
Jul 14

Angiodynamics Q4 Net Income USD -11.4 Million

THOMSON REUTERS
·
Jul 14

Angiodynamics Outlook FY Sales USD 336-341 Million

THOMSON REUTERS
·
Jul 14

Angiodynamics Inc: for Fiscal 2027, Co Expects a Tariff Impact Broadly Similar to Fiscal 2026

THOMSON REUTERS
·
Jul 14

Angiodynamics Q4 Adjusted EPS USD -0.07

THOMSON REUTERS
·
Jul 14

Angiodynamics Outlook FY Adjusted EPS USD -0.29 to -0.24

THOMSON REUTERS
·
Jul 14

Angiodynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-year Profitability

THOMSON REUTERS
·
Jul 14

U.S. Earnings Preview: Before Market Open July 14

Dow Jones
·
Jul 14

Top News Today: Stocks Fall as Chip Makers Slide, Oil Spikes

Dow Jones
·
Jul 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 13

Angiodynamics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Jul 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 08

Press Release: Angiodynamics to Report Fiscal 2026 Fourth Quarter and Full-year Financial Results on July 14, 2026

Dow Jones
·
Jun 30

Angiodynamics to Report Fiscal 2026 Fourth-quarter and Full-year Results, Host Conference Call

Reuters
·
Jun 30

AngioDynamics Secures FDA Approval to Begin Benign Prostatic Hyperplasia Study

MT Newswires Live
·
Jun 17

AngioDynamics wins FDA IDE approval for RELIEF feasibility study of NanoKnife in BPH

Reuters
·
Jun 17

AngioDynamics Receives FDA Ide Approval for Relief Feasibility Study Evaluating Nanoknife Ire Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (Bph)

THOMSON REUTERS
·
Jun 17